AOD9604
Well StudiedModified hGH C-terminal fragment
AOD9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (amino acids 177-191). It has been studied in metabolic research for its effects on lipolysis and fat metabolism pathways, independent of IGF-1 stimulation. Published research has investigated its interaction with the growth hormone receptor and its metabolic effects in laboratory models. RaysunPeptide supplies AOD9604 for qualified research and laboratory applications.
Mechanism of Action
Stimulates lipolysis and inhibits lipogenesis through beta-3 adrenergic receptor upregulation, without binding to the GH receptor. Does not affect glucose metabolism or increase IGF-1 levels.
Key Benefits
Molecular Data
Dosing Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Fat loss - Standard | 250-300mcg | Once daily (morning, fasted) | SubQ |
| Enhanced fat loss | 400-500mcg | Once daily (morning, fasted) | SubQ |
| Joint support | 250mcg | Once daily | SubQ |
| Conservative start | 200mcg | Once daily | SubQ |
Research Indications
Fat Loss
Increases fat oxidation, plasma glycerol levels, and reduces body weight in obese models without affecting glucose metabolism.
Reduces fat synthesis and storage in adipose tissue.
Does not cause hyperglycemia, reduce insulin secretion, or increase insulin resistance.
Joint Health
Enhanced cartilage regeneration when combined with hyaluronic acid in osteoarthritis models.
Synergistic effects with hyaluronic acid for joint health.
Peptide Interactions
Enhanced cartilage repair when combined for joint health.
Different mechanisms; sometimes combined for comprehensive healing.
AOD-9604 doesn't affect GH axis; can be used together.
Different mechanisms; no known interactions.
Complementary weight loss mechanisms through different pathways.
AOD-9604 doesn't affect glucose metabolism unlike full hGH.
What to Expect
Side Effects & Safety
Common (Generally Mild)
- •Generally well-tolerated in clinical trials
- •Mild injection site reactions possible
- •No reported effects on blood glucose or insulin
Stop Signs (Seek Medical Attention)
- ⚠Severe injection site reactions or infection signs
- ⚠Unusual swelling or persistent redness
- ⚠Allergic reactions (rare)
- ⚠Any concerning or unexpected symptoms
Contraindications
- ✕Pregnancy or breastfeeding
- ✕WADA prohibited - athletes subject to testing must avoid
Quality Checklist
Good Signs ✓
- White lyophilized powder with uniform appearance
- Crystal clear solution without particles after reconstitution
- Certificate of Analysis showing >98% purity by HPLC
- Proper cold-chain shipping
Warning Signs !
- Not FDA approved as a therapeutic drug - research chemical only
- WADA prohibited substance
Bad Signs ✕
- Discolored or clumped powder (yellow indicates degradation)
- Cloudy solution after reconstitution
- Collapsed or moisture-damaged appearance
References
Both hGH and AOD-9604 reduced body weight gain, increased fat oxidation, and stimulated lipolysis in obese ob/ob mice after 14 days chronic IP administration, without affecting glucose metabolism.
View on PubMed →Both hGH and AOD-9604 increased repressed beta-3 adrenergic receptor RNA expression in obese mice to levels comparable with lean mice. Effects abolished in beta-3-AR knockout mice, confirming pathway involvement.
View on PubMed →Oral treatment of ob/ob mice with AOD-9401 for 30 days significantly reduced body weight gain and altered lipogenic and lipolytic activity in adipose tissue.
View on PubMed →Characterized metabolic properties of AOD-9604 as a synthetic lipolytic domain of hGH with antilipogenic activity that does not interact with the GH receptor.
View on PubMed →Intra-articular AOD-9604 injections enhanced cartilage regeneration in collagenase-induced osteoarthritis rabbit model. Combined AOD-9604 and hyaluronic acid injections were more effective than either alone.
View on PubMed →FAQs
Does AOD-9604 cause blood sugar problems like full human growth hormone?
No. AOD-9604 is a modified hGH fragment that stimulates lipolysis without binding to the GH receptor or affecting glucose metabolism. Unlike full GH which causes hyperglycemia and insulin resistance, AOD-9604 does not increase IGF-1 levels or disrupt glucose homeostasis, making it metabolically safer.
How quickly will I see fat loss with AOD-9604?
Week 1-2 shows minimal noticeable effects as compound accumulates. Week 3-4 brings subtle body composition changes. Week 5-8 produces more noticeable fat loss especially with diet and exercise. Week 8-12 shows continued fat reduction and improved body composition. Total timeline is slower than GLP-1 agonists.
Can AOD-9604 be stacked with semaglutide or other weight loss peptides?
Yes. AOD-9604's lipolytic mechanism complements semaglutide's appetite suppression through completely different pathways. However, combination data is limited. Both are safe separately; combining requires monitoring for additive dehydration/GI effects common with semaglutide.
Is there any cartilage repair evidence for AOD-9604 in humans?
Animal studies show AOD-9604 combined with hyaluronic acid enhanced cartilage regeneration in osteoarthritis models. However, this is preclinical; human cartilage repair data doesn't exist. Joint health claims should be considered theoretical unless based on clinical trial data.
